For now, Covid vaccine recipients will not get to choose from 2 options

The government hinted that for now, the Covid vaccine recipients will not have the option to choose from the two vaccines approved for restricted emergency use

Coronavirus, vaccine, covid, drugs, clinical trials
Representational image of a Covid-19 vaccine
Press Trust of India New Delhi
2 min read Last Updated : Jan 12 2021 | 8:33 PM IST

The government hinted on Tuesday that for now, the COVID vaccine recipients will not have the option to choose from the two vaccines recently approved for restricted emergency use in India.

Replying to a question at a press conference here, Union Health Secretary Rajesh Bhushan said, "At many places in the world, more than one vaccine are being administered, but presently, in no country, vaccine recipients have the option of choosing the shots."

India has recently approved two vaccines for the viral disease for restricted emergency use -- Oxford University's Covishield and Bharat Biotech's Covaxin.

Bhushan said there will be a gap of 28 days between two doses of the COVID-19 vaccine and its effectiveness can be seen only after 14 days.

"So we urge people to keep following COVID appropriate behaviour," he said.

India will launch its COVID-19 vaccination drive from January 16 with priority to be given to nearly three crore healthcare and frontline workers.

Bhushan said 54.72 lakh of the entire stock of COVID-19 vaccine doses ordered so far were received by the designated national and state-level vaccine stores till Tuesday afternoon, with the coronavirus inoculation drive set to begin from Saturday.

He said all the orders -- 1.1 crore doses of Covishield from the Serum Institute of India and 55 lakh doses of Covaxin from Bharat Biotech -- will be received by January 14.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus TestsAstraZenecaBharat Biotech

First Published: Jan 12 2021 | 8:29 PM IST

Next Story